4.8 Review

Genome-wide association studies: progress and potential for drug discovery and development

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 7, Issue 3, Pages 221-230

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2519

Keywords

-

Funding

  1. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER
  2. NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066569] Funding Source: NIH RePORTER
  4. NCRR NIH HHS [P20 RR016480, P20 RR016480-07] Funding Source: Medline
  5. NIAID NIH HHS [U01AI066,569, U01 AI066569, U01 AI066569-03] Funding Source: Medline
  6. NICHD NIH HHS [U19 HD077693] Funding Source: Medline
  7. PHS HHS [N01A000,064] Funding Source: Medline

Ask authors/readers for more resources

Although genetic studies have been critically important for the identification of therapeutic targets in Mendelian disorders, genetic approaches aiming to identify targets for common, complex diseases have traditionally had much more limited success. However, during the past year, a novel genetic approach - genome-wide association ( GWA) - has demonstrated its potential to identify common genetic variants associated with complex diseases such as diabetes, inflammatory bowel disease and cancer. Here, we highlight some of these recent successes, and discuss the potential for GWA studies to identify novel therapeutic targets and genetic biomarkers that will be useful for drug discovery, patient selection and stratification in common diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available